|
|
Volumn 3 Suppl 2, Issue , 1996, Pages
|
|
Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CONTRAST MEDIUM;
DIAGNOSTIC AGENT;
IRON;
OXIDE;
SUPERPARAMAGNETIC IRON OXIDE;
ARTICLE;
BILE DUCT CARCINOMA;
CLINICAL TRIAL;
DOSE RESPONSE;
HEMANGIOMA;
HUMAN;
LIVER ADENOMA;
LIVER CELL CARCINOMA;
LIVER DISEASE;
LIVER TUMOR;
LYMPHOMA;
METASTASIS;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PHASE 2 CLINICAL TRIAL;
SENSITIVITY AND SPECIFICITY;
ADENOMA, LIVER CELL;
CARCINOMA, HEPATOCELLULAR;
CHOLANGIOCARCINOMA;
CONTRAST MEDIA;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HEMANGIOMA;
HUMANS;
IRON;
LIVER DISEASES;
LIVER NEOPLASMS;
LYMPHOMA;
MAGNETIC RESONANCE IMAGING;
OXIDES;
SENSITIVITY AND SPECIFICITY;
MLCS;
MLOWN;
|
|
EID: 0030210220
PISSN: 10766332
EISSN: None
Source Type: Journal
DOI: 10.1016/s1076-6332(96)80603-9 Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|
